Sage Journals: Discover world-class research

Abstract

Nearly all men with prostate cancer who are treated with androgen deprivation therapy develop disease progression. There is considerable evidence to suggest that CXCL 13 released by tumor cells leads to B-cell infiltration into the prostate cells. This B-cell infiltration has been postulated to play a role in development of disease progression following androgen-deprivation therapies. We present a case of a patient who achieved remission of metastatic castrate-resistant prostate cancer after receiving rituximab and bendamustine for the treatment of follicular lymphoma. The findings in this report suggest that further investigation is warranted for utilizing B-cell targeted therapy in delaying progression of castrate-resistant prostate cancer.

Keywords

Castrate resistant prostate cancer Rituximab

Get full access to this article

View all access options for this article.

References

Halabi

Lin

Kelly

et al.

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2014; 32: 671–677.

Berthold

Pond

Soban

et al.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242–245.

Tannock

de Wit

Berry

et al.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004; 351: 1502–1512.

Petrylak

Tangen

Hussain

et al.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004; 351: 1513–1520.

De Bono

Logothetis

Molina

et al.

Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 2011; 364: 1995–2005.

Scher

Fizazi

Saad

et al.

Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012; 367: 1187–1197.

Strasner

Karin

. Immune infiltration and prostate cancer. Frontier Oncol 2015; 5: 128–128.

Ammirante

Shalapour

Kang

et al.

Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci 2014; 111: 14776–14781.

Ammirante

Luo

Grivennikov

et al.

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464: 302–302.

10.

Ammirante

Kuraishy

Shalapour

et al.

An IKKα–E2F1–BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Develop 2013; 27: 1435–1440.

11.

Reddy

Guan

Qin

et al.

Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy. Prostate 2011; 71: 1796–1809.

12.

Woo

Liss

Muldong

et al.

Tumor infiltrating B-cells are increased in prostate cancer tissue. J Translat Med 2014; 12: 30–30.

13.

Dalgleish

Featherstone

Vlassov

et al.

Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature. Investigat New Drugs 2014; 32: 1048–1052.

14.

Hanna F, Prakash A, Allan E, et al. Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin’s lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy. BMJ Case Rep. Published Online First: doi:10.1136/bcr-2017-223637.

15.

Stephen H. Rituximab neoadjuvant therapy in patients with prostate cancer scheduled to undergo radical prostatectomy. Bethesda, MD: National Library of Medicine (US), 2000, https://clinicaltrials.gov/ct2/show/NCT01804712 (accessed 8 April 2018).

Potential role of rituximab in metastatic castrate-resistant prostate cancer

Abstract

Keywords

Get full access to this article

References